Glycyx

San Francisco, CA

Glycyx has developed a minimally-toxic cancer therapy that can turn immunologically cold tumors hot. Our lead candidate, axelopran, blocks a fundamental injury response pathway to increase immune infiltration of the tumor microenvironment (TME) and maintain effector phenotype, reducing tumor growth and preventing T-cell exhaustion. Immune potentiation is selectively targeted to the TME, avoiding systemic immune side effects.